Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986521 in Healthy Adult Participants
NCT07283263Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986521 (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Treatment-Emergent Adverse Events at 40 days, Treatment-Emergent Serious Adverse Events at 40 days and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
BMS-986521
Beyond the preview
Go deeper on NCT07283263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283263.